Ventricular tachycardia (VT) most commonly develops in patients with structural heart disease. Myocardial infarction results in collagen replacement interspersed with surviving myocardium, which alters impulse propagation, facilitating re-entry. Aside from the postinfarction substrate, scar-mediated VT occurs in patients with nonischemic cardiomyopathy, Chagas disease, sarcoidosis, arrhythmogenic right ventricular cardiomyopathy, and postsurgical congenital heart disease. In structurally normal hearts, VT results from intracellular calcium overload or an abnormal response to adrenergic stimulation, promoting triggered activity or automaticity, respectively.

There are 3 treatment options for VT, although many patients require a combination: an implantable cardioverter-defibrillator (ICD), antiarrhythmic medications, and catheter ablation. An ICD provides abortive “rescue” therapy but cannot prevent the heart from going into VT. Antiarrhythmic therapy has limited efficacy and has the potential for multiple side effects, including proarrhythmia.

In this Clinician Update, we discuss 3 different VT clinical scenarios that are amenable to catheter ablation to highlight the range of substrate-specific strategies used in the electrophysiology laboratory.

**Case 1: Symptomatic Premature Ventricular Contractions With Cardiomyopathy**

An 18-year-old man presented with palpitations and fatigue. Over a period of 5 months, he had been unable to play sports owing to dyspnea on exertion. A resting ECG demonstrated sinus rhythm with frequent monomorphic premature ventricular contractions. An echocardiogram revealed an ejection fraction of 35% with global hypokinesis. Previous treatment with β-blockers and flecainide was unsuccessful, and he was referred for evaluation for catheter ablation.

The patient underwent electrophysiological study, and activation mapping was performed in the right and left ventricular outflow tracts to locate the earliest site of origin. A single application of radiofrequency energy at the earliest site below the left coronary cusp resulted in complete abolition of the premature ventricular contractions (Figure 1).

Frequent premature ventricular contractions are an underrecognized, reversible cause of idiopathic cardiomyopathy. A correlation with the burden of premature ventricular contractions with cardiomyopathy has been reported, with higher risk at a burden of >20% on Holter analysis. Catheter ablation is recommended for patients with symptomatic monomorphic ventricular ectopy when medications are not effective, tolerated, or desired, particularly in those with diminished systolic function. Ablation can result in elimination of premature ventricular contractions in >80% of cases, with resolution of cardiomyopathy.

Two months later, the patient had a repeat echocardiogram that showed normalization of the systolic function with an ejection fraction of 55%. His fatigue resolved, and he was able to participate in sports again.

**Case 2: Recurrent Implantable Cardioverter-Defibrillator Shocks in Ischemic Cardiomyopathy**

A 71-year-old man with history of inferior myocardial infarction and an ejection fraction of 25% presented to the emergency department with 4 ap-
propriate ICD shocks in a 48-hour period. Amiodarone was initiated, and the patient presented 3 weeks later with lightheadedness; device interrogation showed 35 episodes of VT at a rate of 140 bpm, which were terminated with antitachycardia pacing over the prior 10 days. The patient was referred for catheter ablation.

A basal inferolateral scar was confirmed by contrast-enhanced computed tomography scan (3-dimensional reconstruction), and electroanatomic mapping and late potentials within the scar demonstrated excellent pace-map matches (Figure 2A). Clinical VT was induced, and entrainment mapping demonstrated proof of a critical isthmus with diastolic activity. Ablation at this site resulted in prompt termination of the VT (Figure 2B). Amiodarone was discontinued, and the patient experienced an improved quality of life without any ICD therapies in the following 10 months.

Fewer than 20% of VTs are hemodynamically stable to enable mapping during VT. In these instances, activity during diastole (pre-QRS) is sought because this represents slow conduction within the scar before it exits the circuit and captures the myocardium, represented by the QRS (Figure 2B). Critical isthmuses exhibit specific responses to entrainment mapping6 (Table 1). The majority of ischemic cardiomyopathy patients have multiple inducible VTs, and when VT is not hemodynamically tolerated, a substrate-based ablation strategy dependent on the identification of late potentials (areas of slow conduction) and pace mapping is implemented. Single-center experience and multicenter registries demonstrate an efficacy of 50% to 75% at 6 to 12 months.7

Case 3: Ventricular Tachycardia Storm in Nonischemic Cardiomyopathy With Epicardial Ablation

A 66-year-old woman with idiopathic dilated cardiomyopathy and an ejec-
tion fraction of 25% was admitted for 2 ICD shocks from her biventricular ICD and heart failure. While being treated with diuresis, amiodarone, and inotropes, the patient developed 6 ICD shocks in a 24-hour period. A lidocaine drip was added; the patient was sedated and intubated; and an intraaortic balloon pump was placed.

Because the surface ECG exhibited delayed QRS upstroke or late intrinsicoid deflection suggesting an epicardial focus, a combined epi-endo approach for mapping and ablation was undertaken (Figure 3). Epicardial access was obtained before anticoagulation with heparin following the technique described by Sosa et al,8 and endocardial access was obtained via a transseptal approach on full anticoagulation. Mapping within the pericardial space revealed a significantly greater extent of scar on the epicardium compared with the endocardium in the basal lateral region (see Figure 3). Ventricular tachycardia was induced and was not hemodynamically tolerated, requiring immediate cardioversion. Pace mapping demonstrated a better match from the epicardium than the endocardium. Epicardial ablation was performed at the site of perfect pace map. A second poorly tolerated VT was induced, and pace mapping from the endocardium in the annular scar region revealed the best match. Ablation was performed in this region, and the patient was rendered noninducible. She remained free of VT recurrence for 2 weeks, and her hemodynamic profile improved on inotropes. She was discharged home after a transition to oral medications.

The deleterious effects of ICD shocks, appropriate and inappropriate, in patients with advanced heart failure have been well documented.9,10 Whether VT is merely a surrogate for pump deterioration or ICD shocks are directly injurious to myocardial function remains unclear. Nevertheless, recurrent VT necessitating ICD therapy is commonly seen with decompensated heart failure and vice versa.
A VT storm is defined as >3 episodes of VT within a 24-hour period. Treatment with intravenous amiodarone, lidocaine, and/or procainamide is first line. Sedation and insertion of an intra-aortic balloon pump are often necessary to decrease adrenergic stimulation and to optimize hemodynamics. In this setting, titration of inotropes must be done with caution. Neuraxial modulation has been shown to be effective in cases refractory to

Figure 2. A, Correlation of computed tomography scan and electroanatomic map showing basal inferolateral aneurysmal scar. Left, A late potential within this scar yields a perfect pace map of the targeted ventricular tachycardia (right). B, A 12-lead ECG of ventricular tachycardia with middiastolic activity (boxes) recorded on ablation catheter (Abl; left). Theoretical construct of intramural scar-mediated reentry with diastolic activity recorded in the isthmus (electrodes 1 through 5) before exiting the circuit (bold arrow) between 2 areas of collagen (blue) on trichrome staining of an experimental infarction. Prompt termination of ventricular tachycardia during ablation (Abl:ON) at the site demonstrating concealed entrainment (bottom).
Table 1. Mapping Techniques for Catheter Ablation of Ventricular Tachycardia

Hemodynamically stable VT
- Activation mapping
  - Idiopathic (triggered or automatic): earliest site of origin
  - Scar-mediated (reentry): diastolic activity
    - Presystolic (<30% TCL) = exit
    - Middiastolic (30%–70% TCL) = isthmus
    - Early diastolic (>70% TCL) = entrance
  - Entrainment mapping of isthmus
  - Concealed fusion
  - PPI=TCL
  - S-QRS=EGM-QRS

Hemodynamically unstable VT
- Electroanatomic substrate mapping/scar delineation
- Pace mapping
- Targeting of late potentials
- Linear ablation lesions sets
  - Scar border zones
  - Scar transection
  - Connecting scars and anatomic boundaries, ie, annulus
- Mechanical hemodynamic support, ie, IABP, LVAD

VT indicates ventricular tachycardia; TCL, tachycardia cycle length; PPI, postspacing interval; S-QRS, stimulus to QRS; EGM-QRS, electrogram to QRS; IABP, intra-aortic balloon pump; and LVAD, left ventricular assist device.

Table 2. Management of Ventricular Tachycardia Storm

<table>
<thead>
<tr>
<th>Hemodynamically stable VT</th>
<th>Hemodynamically unstable VT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiarrhythmic drug therapy</td>
<td>Electroanatomic substrate mapping/scar delineation</td>
</tr>
<tr>
<td>Intubation, deep sedation</td>
<td>Pace mapping</td>
</tr>
<tr>
<td>Mechanical hemodynamic support, ie,</td>
<td>Targeting of late potentials</td>
</tr>
<tr>
<td>IABP, LVAD</td>
<td>Linear ablation lesions sets</td>
</tr>
<tr>
<td></td>
<td>Scar border zones</td>
</tr>
<tr>
<td></td>
<td>Scar transection</td>
</tr>
<tr>
<td></td>
<td>Connecting scars and anatomic boundaries, ie, annulus</td>
</tr>
</tbody>
</table>

Catheter ablation of VT has evolved significantly over the past 2 decades with conceptual and technological advancements. Patients with advanced cardiomyopathy who develop VT are at high risk for morbidity and mortality; procedural complications, which include stroke (<1%), tamponade (1% to 3%), and death (1%), have been shown to be acceptably low in experienced centers. The results of multicenter registries and Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia (SMASH-VT), the first randomized trial in VT ablation, have prompted the paradigm shift from use of catheter ablation as a last-resort palliation to a preemptive strategy for the management of recurrent VT.

Disclosures
None.
References